61 related articles for article (PubMed ID: 7628759)
1. Bcl-2 oncoprotein expression in acute myeloid leukemia.
Bensi L; Longo R; Vecchi A; Messora C; Garagnani L; Bernardi S; Tamassia MG; Sacchi S
Haematologica; 1995; 80(2):98-102. PubMed ID: 7628759
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia.
Schaich M; Illmer T; Seitz G; Mohr B; Schäkel U; Beck JF; Ehninger G
Haematologica; 2001 May; 86(5):470-7. PubMed ID: 11410409
[TBL] [Abstract][Full Text] [Related]
3. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
[TBL] [Abstract][Full Text] [Related]
5. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia.
van Stijn A; van der Pol MA; Kok A; Bontje PM; Roemen GM; Beelen RH; Ossenkoppele GJ; Schuurhuis GJ
Haematologica; 2003 May; 88(5):497-508. PubMed ID: 12745269
[TBL] [Abstract][Full Text] [Related]
6. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
7. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
8. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia.
Venditti A; Del Poeta G; Maurillo L; Buccisano F; Del Principe MI; Mazzone C; Tamburini A; Cox C; Panetta P; Neri B; Ottaviani L; Amadori S
Haematologica; 2004 Aug; 89(8):934-9. PubMed ID: 15339676
[TBL] [Abstract][Full Text] [Related]
9. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.
van Stijn A; Kok A; van der Pol MA; Feller N; Roemen GM; Westra AH; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2003 Apr; 17(4):780-6. PubMed ID: 12682637
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study.
Klobusická M; Kusenda J; Babusíkova O
Neoplasma; 2001; 48(6):489-95. PubMed ID: 11949843
[TBL] [Abstract][Full Text] [Related]
11. Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone.
Lotem J; Sachs L
Cell Growth Differ; 1995 Jun; 6(6):647-53. PubMed ID: 7669718
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
13. Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1.
DiGiuseppe JA; Kastan MB; Weng LJ; Gore SD
In Vivo; 1999; 13(1):1-6. PubMed ID: 10218124
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
[TBL] [Abstract][Full Text] [Related]
15. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
Ahmed N; Laverick L; Sammons J; Zhang H; Maslin DJ; Hassan HT
Anticancer Res; 2001; 21(5):3519-23. PubMed ID: 11848518
[TBL] [Abstract][Full Text] [Related]
16. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis.
Molica S; Mannella A; Dattilo A; Levato D; Iuliano F; Peta A; Consarino C; Magro S
Haematologica; 1996; 81(4):302-9. PubMed ID: 8870373
[TBL] [Abstract][Full Text] [Related]
19. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.
Tamm I; Richter S; Oltersdorf D; Creutzig U; Harbott J; Scholz F; Karawajew L; Ludwig WD; Wuchter C
Clin Cancer Res; 2004 Jun; 10(11):3737-44. PubMed ID: 15173080
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients.
Daneshbod Y; Amirghofran Z; Tabei SZ
Neoplasma; 2005; 52(2):109-14. PubMed ID: 15800708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
